** Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by distributors, and said the problems would persist in the current quarter
PLETHORA OF CATALYSTS AT PLAY
** J.P. Morgan ("Neutral", PT: $95) says there are reasons to stay more positive into FY26 with growth in co's diabetes and heart device business, along with contribution from new products which are used for procedures such as renal denervation and pulsed field ablation
** RBC Capital markets ("Outperform", PT: $105) says MDT has "plethora of catalysts at play" including its surgical robot Hugo and expansion in its portfolio for cardiac devices, along with significant opportunity in renal denervation
** UBS ("Neutral", PT: $95) sees potential for continued improvement in diabetes segment
** Citi ("Neutral", PT: $92) says Medtronic is standing on the threshold of several new growth drivers that are starting to gain traction
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.